VIVO
Commercial- Indications
- Chronic pain, Back pain
Company intelligence / Profile preview
Aurimod
Vienna, Vienna, Austriaaurimod.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
VIVO, the company’s lead product, has demonstrated clinically proven and sustainable therapeutic effects for chronic low back pain and migraine. The device offers non-pharmacological, minimally invasive neuromodulation via auricular vagus nerve stimulation. It has been commercialized in Austria with positive initial results.[1][2][3] Patent protection has been filed for the core technology.[4][5]
- Therapeutic areas
- Neurology
- Modalities
- DeviceNon-pharmacological therapyNeuromodulation device (wearable)
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Aurimod.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aurimod.